Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials
/in Dendritic Cells, International Publications, Malignant Melanoma, Malignant Pleural Mesothelioma /von 2021-05-19 / Vaccines (Basel) 2021 May;9(5)CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper T cell responses against breast cancer stem cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2021-05-19 / Mol Ther Oncolytics 2021 Sep;22:64-71Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I/II trial
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2021-05-14 / Ther Apher Dial 2021 Aug;25(4):415-424Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2021-05-12 / Cancer Med 2021 Jul;10(13):4302-4311A bibliometric review of oncolytic virus research as a novel approach for cancer therapy
/in International Publications, Newcastle Disease Virus /von 2021-05-12 / Virol J 2021 May;18(1):98Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2021-05-10 / Front Oncol 2021;11:672508MicroRNA-204 plays a role as a tumor suppressor in Newcastle disease virus-induced oncolysis in lung cancer A549 cells
/in International Publications, Newcastle Disease Virus, NSCLC /von 2021-04-21 / Oncol Lett 2021 Jun;21(6):482Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways
/in Curcuma, International Publications /von 2021-04-12 / Front Oncol 2021;11:660712Curcumin and cancer biology: Focusing regulatory effects in different signalling pathways
/in Curcuma, International Publications /von 2021-04-09 / Phytother Res 2021 Sep;35(9):4913-4929
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de